Clinical trials: Small-Cell Lung Cancer, open to volunteers
Lung Non-Small Cell Carcinoma
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
This clinical trial studies how well exercise training works in improving immune activity and treatment tolerance and response in patients with non-small cell lung cancer (NSCLC) who are receiving immunotherapy.
- Trial name
- NCT06983899
- Testing
- Aerobic Exercise, Exercise Intervention, Educational Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT06518057
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Gastric Cancer, Colorectal Cancer
Development and Utilization of an Integrated Clinical Genomic Database
This observational study aims to develop an integrated genomic and clinical database to support the discovery and validation of biomarkers for cancer diagnosis, treatment selection, and prediction of treatment response.
- Conditions
- Gastric Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Liver Cancer
- Trial name
- SMC-4S (NCT07911267)
- Where
- South Korea
- Volunteers
- 118,750 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
NSCLC (Advanced Non-small Cell Lung Cancer)
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
This prospective, single-arm, exploratory multicenter clinical study aims to investigate the safety and efficacy of Becotatug vedotin combined with Pucotenlimab (with or without radiotherapy), followed by Pucotenlimab maintenance…
- Trial name
- PRAD2 (NCT07627321)
- Testing
- Pucotenlimab, Becotatug vedotin, Radiotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Anhui Provincial Cancer Hospital
Nonsmall-cell Lung Cancer
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
- Trial name
- NCT06813365
- Testing
- DZD6008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Dizal Pharmaceuticals
Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
- Trial name
- NCT06424665
- Testing
- FZ-AD005
- Where
- 3 sites in China
- Volunteers
- 162 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Trial name
- NCT06764771
- Testing
- BMS-986488, Adagrasib, Cetuximab
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer, Hyperlipidemia
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
The goal of this observational study is to learn about the long-term effects of Lorlatinib related hyperlipidemia in NSCLC patients who take Lorlatinib for at least 21 days.
- Trial name
- NCT06876675
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Third Hospital
NSCLC
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Major objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.
- Trial name
- NCT07379398
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with SBRT
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
- Trial name
- NCT06922539
- Testing
- Fenretinide
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- SciTech Development, Inc.
Non-Small-Cell Lung Cancer
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based…
- Trial name
- KANNON-5 (NCT07336732)
- Testing
- PLB1004
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Lung Cancer, Lung Cancer Metastatic
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer
- Trial name
- NCT05452005
- Testing
- [18F]-αvβ6-BP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Non-Small Cell Lung Cancer (NSCLC), Rehabilitation
The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms
This study aims to develop and evaluate an integrated perioperative management system based on wearable devices and a digital rehabilitation platform for patients with non-small cell lung cancer (NSCLC) undergoing thoracic…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Rehabilitation, Thoracic Surgery, Perioperative Management
- Trial name
- NCT07310056
- Testing
- Wearable-Based Digital Perioperative Rehabilitation System, Standard Perioperative Rehabilitation Guidance
- Where
- China
- Volunteers
- 126 people
- Sponsor
- West China Hospital
Solid Tumor
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with…
- Trial name
- NCT04300556
- Testing
- Farletuzumab ecteribulin, Prednisone, Prednisolone
- Where
- 58 sites in United States, France and 3 more
- Volunteers
- 182 people
- Sponsor
- Eisai Inc.
Non Small Cell Lung Cancer
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
- Trial name
- NCT07070440
- Testing
- DZD6008, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Dizal Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
- Trial name
- NCT07046923
- Testing
- LY4175408, Pembrolizumab, Carboplatin
- Where
- 27 sites in United States, China and 4 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-small Cell Lung Cancer, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06612840
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose [RP2CD]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents…
- Trial name
- KaRAnaSa (NCT07227025)
- Testing
- Amivantamab, Olomorasib
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Carcinoma (NSCLC)
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell…
- Trial name
- NCT07362459
- Testing
- SCTB14, Pembrolizumab
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sinocelltech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.